peginterferon beta-1a
Sign in to savepharmaceutical drug
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2014
- Admin. routes
- parenteral
- Indications
- relapsing-remitting multiple sclerosis, Renal insufficiency, neoplasm, multiple sclerosis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 2 more facts
- defined daily dose
- 8.9
- has characteristic
- biopharmaceutical
via Wikidata · CC0